PE20080181A1 - Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer - Google Patents
Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimerInfo
- Publication number
- PE20080181A1 PE20080181A1 PE2007000354A PE2007000354A PE20080181A1 PE 20080181 A1 PE20080181 A1 PE 20080181A1 PE 2007000354 A PE2007000354 A PE 2007000354A PE 2007000354 A PE2007000354 A PE 2007000354A PE 20080181 A1 PE20080181 A1 PE 20080181A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- beta
- peptide
- alzheimer
- treatment
- Prior art date
Links
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE COMPRENDE LAS SIGUIENTES CDR: CDRH1: SEC ID N0:1; CDRH2: SEC ID N0: 2; CDRH3: SEC ID N0:3; SEC ID N0: 3DENTRO DE UNA REGION VARIABLE DE CADENA PESADA HUMANA PROCEDENTE DE LA FAMILIA GENICA VH3 Y CDRL1: SEC ID N0:4; CDRL2: SEC ID N0:5; CDRL3: SEC ID N0: 6 DENTRO DE UNA REGION VARIABLE DE CADENA LIGERA HUMANA PROCEDENTE DE LA SECUENCIA DE AMINOACIDOS DESCRITA EN GENPEPT SEC ID N0:24. EL ANTICUERPO SE UNE AL PEPTIDO BETA-AMILIODE 1-12 CON UNA CONSTANTE DE EQUILIBRIO KD MENOR DE 100 pM Y TIENE UNA CONSTANTE DE EQUILIBRIO KD PARA LA UNION AL PEPTIDO BETA-AMILIODE 2-13 QUE SE 1000 VECES MAYOR QUE LA DEL PEPTIDO 1-12. DICHO ANTICUERPO ES UN ISOTOPO IgG1 UTIL EN EL TRATAMIENTO DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78758806P | 2006-03-30 | 2006-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080181A1 true PE20080181A1 (es) | 2008-03-16 |
Family
ID=38284050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000354A PE20080181A1 (es) | 2006-03-30 | 2007-03-28 | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US8227576B2 (es) |
| EP (2) | EP2177536B1 (es) |
| JP (1) | JP5103466B2 (es) |
| KR (2) | KR101263294B1 (es) |
| CN (2) | CN103539857A (es) |
| AR (1) | AR060332A1 (es) |
| AT (1) | ATE451392T1 (es) |
| AU (1) | AU2007233831B2 (es) |
| BR (1) | BRPI0709246A2 (es) |
| CA (1) | CA2647808C (es) |
| CR (1) | CR10347A (es) |
| CY (1) | CY1109877T1 (es) |
| DE (1) | DE602007003703D1 (es) |
| DK (2) | DK1996621T3 (es) |
| EA (1) | EA015654B9 (es) |
| ES (2) | ES2338179T3 (es) |
| HR (2) | HRP20100115T1 (es) |
| IL (1) | IL193695A (es) |
| JO (1) | JO2576B1 (es) |
| MA (1) | MA30337B1 (es) |
| MX (1) | MX2008012483A (es) |
| MY (1) | MY149630A (es) |
| NO (1) | NO20083793L (es) |
| NZ (1) | NZ571038A (es) |
| PE (1) | PE20080181A1 (es) |
| PL (2) | PL2177536T3 (es) |
| PT (2) | PT2177536E (es) |
| SI (2) | SI2177536T1 (es) |
| TW (1) | TWI385179B (es) |
| UA (1) | UA94734C2 (es) |
| WO (1) | WO2007113172A2 (es) |
| ZA (1) | ZA200807911B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| PT1583562E (pt) | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, compostos relacionados, e suas utilizações |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| TW200635607A (en) | 2004-12-15 | 2006-10-16 | Elan Pharm Inc | Humanized Aβ antibodies for use in improving cognition |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| ES2527661T3 (es) | 2005-11-30 | 2015-01-28 | Abbvie Inc. | Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| KR101605207B1 (ko) | 2006-07-14 | 2016-03-22 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| KR101637533B1 (ko) * | 2007-08-20 | 2016-07-11 | 글락소 그룹 리미티드 | 제조 방법 |
| GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
| EP2238166B1 (en) | 2007-10-05 | 2013-11-27 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| SG185277A1 (en) * | 2007-10-05 | 2012-11-29 | Genentech Inc | Humanized antibody |
| LT2592148T (lt) * | 2007-10-12 | 2018-12-10 | F. Hoffmann-La Roche Ag | Baltymų ekspresavimas iš kelių nukleorūgščių |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2586797A3 (en) * | 2007-11-27 | 2013-07-24 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| UY31520A1 (es) * | 2007-12-11 | 2009-08-03 | Proteinas de union a antigenos | |
| WO2009085200A2 (en) * | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| CL2009001080A1 (es) | 2008-05-06 | 2010-09-24 | Glaxo Group Ltd | Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo. |
| EP2346906A4 (en) | 2008-10-15 | 2013-04-24 | Angiochem Inc | CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| EP2448965A4 (en) * | 2009-07-02 | 2015-02-11 | Angiochem Inc | MULTIMEPEPTID CONJUGATES AND ITS USES |
| SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
| CN102781962B (zh) | 2010-03-03 | 2014-12-10 | 阿布林克斯公司 | 双互补位A-β结合多肽 |
| CN102933601B (zh) | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| WO2011149461A1 (en) * | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| KR102052571B1 (ko) | 2010-11-30 | 2019-12-05 | 제넨테크, 인크. | 저친화도 혈액-뇌 장벽 수용체 항체 및 그의 용도 |
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| JP2014518615A (ja) | 2011-04-22 | 2014-08-07 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法 |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| MY181743A (en) | 2012-05-21 | 2021-01-06 | Genentech Inc | Methods for improving safety of blood-brain barrier transport |
| RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
| EP3011343A2 (en) | 2013-06-19 | 2016-04-27 | Glaxosmithkline Intellectual Property (No. 2) Limited | Assay for complement factor i (cfi) bioactivity |
| CN104558172A (zh) * | 2015-01-04 | 2015-04-29 | 东南大学 | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| HK1251480A1 (zh) | 2015-09-21 | 2019-02-01 | Aptevo Research And Development Llc | Cd3结合多肽 |
| WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| AU2018290898B2 (en) * | 2017-06-29 | 2021-03-11 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies for treatment of amyloid deposition diseases |
| US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| US12018069B2 (en) | 2018-06-28 | 2024-06-25 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for imaging amyloid deposits |
| US12325741B2 (en) * | 2018-07-17 | 2025-06-10 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-Aβ antibodies and antigen-binding fragments thereof |
| EP3946605A1 (en) | 2019-04-05 | 2022-02-09 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN114591918B (zh) * | 2022-05-07 | 2022-07-26 | 北京第一生物化学药业有限公司 | 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途 |
| CN114591917B (zh) * | 2022-05-07 | 2022-09-02 | 北京第一生物化学药业有限公司 | 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途 |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
| CN118638219B (zh) * | 2024-08-19 | 2024-11-22 | 成都迈科康生物科技有限公司 | 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811517A (en) * | 1992-01-27 | 1998-09-22 | Icos Corporation | ICAM-related protein variants |
| DE69839808D1 (de) * | 1997-04-09 | 2008-09-11 | Intellect Neurosciences Inc | Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung |
| US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| EP1133699A1 (en) * | 1998-11-25 | 2001-09-19 | Scios Inc. | Prevention and treatment of amyloid-associated disorders |
| KR100767146B1 (ko) * | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| DE60134430D1 (de) * | 2000-11-03 | 2008-07-24 | David Gladstone Inst | Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| ITTO20020867A1 (it) * | 2002-10-08 | 2004-04-09 | Pro Cord Spa | Schienale di sedia. |
| KR20050071564A (ko) * | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 |
-
2007
- 2007-03-27 US US12/294,438 patent/US8227576B2/en not_active Expired - Fee Related
- 2007-03-27 BR BRPI0709246-6A patent/BRPI0709246A2/pt not_active IP Right Cessation
- 2007-03-27 EA EA200801842A patent/EA015654B9/ru not_active IP Right Cessation
- 2007-03-27 CN CN201310338011.6A patent/CN103539857A/zh active Pending
- 2007-03-27 ES ES07727401T patent/ES2338179T3/es active Active
- 2007-03-27 DE DE602007003703T patent/DE602007003703D1/de active Active
- 2007-03-27 WO PCT/EP2007/052928 patent/WO2007113172A2/en not_active Ceased
- 2007-03-27 EP EP09178407.4A patent/EP2177536B1/en not_active Not-in-force
- 2007-03-27 MX MX2008012483A patent/MX2008012483A/es active IP Right Grant
- 2007-03-27 PL PL09178407T patent/PL2177536T3/pl unknown
- 2007-03-27 PT PT91784074T patent/PT2177536E/pt unknown
- 2007-03-27 UA UAA200810923A patent/UA94734C2/ru unknown
- 2007-03-27 HR HR20100115T patent/HRP20100115T1/hr unknown
- 2007-03-27 DK DK07727401.7T patent/DK1996621T3/da active
- 2007-03-27 SI SI200731503T patent/SI2177536T1/sl unknown
- 2007-03-27 CA CA2647808A patent/CA2647808C/en not_active Expired - Fee Related
- 2007-03-27 EP EP07727401A patent/EP1996621B1/en not_active Not-in-force
- 2007-03-27 JP JP2009502072A patent/JP5103466B2/ja not_active Expired - Fee Related
- 2007-03-27 KR KR1020087026640A patent/KR101263294B1/ko not_active Expired - Fee Related
- 2007-03-27 CN CN2007800124360A patent/CN101415729B/zh not_active Expired - Fee Related
- 2007-03-27 DK DK09178407.4T patent/DK2177536T3/da active
- 2007-03-27 SI SI200730173T patent/SI1996621T1/sl unknown
- 2007-03-27 PT PT07727401T patent/PT1996621E/pt unknown
- 2007-03-27 AT AT07727401T patent/ATE451392T1/de active
- 2007-03-27 ES ES09178407.4T patent/ES2484967T3/es active Active
- 2007-03-27 KR KR1020127016745A patent/KR20120093400A/ko not_active Withdrawn
- 2007-03-27 NZ NZ571038A patent/NZ571038A/en not_active IP Right Cessation
- 2007-03-27 AU AU2007233831A patent/AU2007233831B2/en not_active Ceased
- 2007-03-27 PL PL07727401T patent/PL1996621T3/pl unknown
- 2007-03-28 AR ARP070101295A patent/AR060332A1/es not_active Application Discontinuation
- 2007-03-28 JO JO200788A patent/JO2576B1/en active
- 2007-03-28 PE PE2007000354A patent/PE20080181A1/es not_active Application Discontinuation
- 2007-03-28 TW TW096110663A patent/TWI385179B/zh not_active IP Right Cessation
-
2008
- 2008-08-26 IL IL193695A patent/IL193695A/en not_active IP Right Cessation
- 2008-09-03 NO NO20083793A patent/NO20083793L/no not_active Application Discontinuation
- 2008-09-15 ZA ZA200807911A patent/ZA200807911B/xx unknown
- 2008-09-26 MY MYPI20083843A patent/MY149630A/en unknown
- 2008-10-07 CR CR10347A patent/CR10347A/es unknown
- 2008-10-15 MA MA31293A patent/MA30337B1/fr unknown
-
2010
- 2010-03-01 CY CY20101100198T patent/CY1109877T1/el unknown
-
2012
- 2012-06-08 US US13/491,810 patent/US9193784B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 HR HRP20140618TT patent/HRP20140618T1/hr unknown
-
2015
- 2015-10-13 US US14/881,428 patent/US20160024197A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| JP2020500538A5 (es) | ||
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| AR068723A1 (es) | Proteina que se une a antigenos que se une a il-23 humana y sus usos | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| RU2588467C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| PE20120554A1 (es) | Polipeptidos y metodo de tratamiento | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| HRP20170882T1 (hr) | Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| PE20131400A1 (es) | Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9) | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| PE20080214A1 (es) | Moleculas de anticuerpo que se unen a la il-17 humana | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| PE20090768A1 (es) | Metodos y composiciones para el tratamiento de enfermedades alergicas | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |